Recent Updates
Recently added Catalysts

CT-322

Phase 1

Cancer | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: Feb 24, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00374179CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's LymphomaPHASE1 COMPLETED 40 — — Aug 1, 2006Feb 1, 2009Feb 24, 20093 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and tolerability of CT-322
Throughout the study
Secondary Endpoints
To evaluate the pharmacokinetics of CT-322 in these patients;
Throughout the study
to assess whether antibodies to this drug develop in these patients; and
Throughout the study
to make a preliminary assessment of the biological activity of CT-322 to alter tumor growth.
Throughout the study
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
CT-322DRUGIV solution, weekly or bi-weekly
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites3

DISEASE CHARACTERISTICS * Histologically proven advanced solid malignancy or NHL for which no standard therapy exists or for which standard therapy had failed * No known brain or leptomeningeal disease * No prior bone marrow transplant or stem cell rescue * No histologically confirmed squamous non-...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Cancer 5 trials
CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520 / GEH200521 - Part A
Zimmer Biomet Holdings, Inc.ZBH1 — Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence